Abstract:
BACKGROUND:Community-based health insurance (CBHI) schemes have been introduced in low- and middle-income countries to increase health service utilization and provide financial protection from high healthcare expenditures. OBJECTIVE:We assess the impact of household size on decisions to enroll in CBHI and demonstrate how to correct for group disparity in scale (i.e. variance differences). METHODS:A discrete choice experiment was conducted across five CBHI attributes. Preferences were elicited through forced-choice paired comparison choice tasks designed based on D-efficiency. Differences in preferences were examined between small (1-4 family members) and large (5-12 members) households using conditional logistic regression. Swait and Louviere test was used to identify and correct for differences in scale. RESULTS:One-hundred and sixty households were surveyed in Northwest Cambodia. Increased insurance premium was associated with disutility [odds ratio (OR) 0.61, p < 0.01], while significant increase in utility was noted for higher hospital fee coverage (OR 10.58, p < 0.01), greater coverage of travel and meal costs (OR 4.08, p < 0.01), and more frequent communication with the insurer (OR 1.33, p < 0.01). While the magnitude of preference for hospital fee coverage appeared larger for the large household group (OR 14.15) compared to the small household group (OR 8.58), differences in scale were observed (p < 0.05). After adjusting for scale (k, ratio of scale between large to small household groups = 1.227, 95 % confidence interval 1.002-1.515), preference differences by household size became negligible. CONCLUSION:Differences in stated preferences may be due to scale, or variance differences between groups, rather than true variations in preference. Coverage of hospital fees, travel and meal costs are given significant weight in CBHI enrollment decisions regardless of household size. Understanding how community members make decisions about health insurance can inform low- and middle-income countries' paths towards universal health coverage.
journal_name
Appl Health Econ Health Policyjournal_title
Applied health economics and health policyauthors
Ozawa S,Grewal S,Bridges JFdoi
10.1007/s40258-016-0222-9subject
Has Abstractpub_date
2016-04-01 00:00:00pages
195-204issue
2eissn
1175-5652issn
1179-1896pii
10.1007/s40258-016-0222-9journal_volume
14pub_type
杂志文章abstract:BACKGROUND:Low back pain (LBP) is a major health problem, having a substantial effect on peoples' quality of life and placing a significant economic burden on healthcare systems and, more broadly, societies. Many interventions to alleviate LBP are available but their cost effectiveness is unclear. OBJECTIVES:To identi...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-016-0268-8
更新日期:2017-04-01 00:00:00
abstract::A routine part of the process for developing National Institute for Health and Care Excellence (NICE) medical technologies guidance is a submission of clinical and economic evidence by the technology manufacturer. The Birmingham and Brunel Consortium External Assessment Centre (EAC; a consortium of the University of B...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0117-6
更新日期:2014-10-01 00:00:00
abstract::This article deals with the accuracy of statistical records used for political decision making and international comparative analysis. In developing countries, even major macroeconomic indicators can include data inadequacies and methodological differences in data generation between statistical agencies. Existing data...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11595230-000000000-00000
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0440-4
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-015-0180-7
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256160
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:It is estimated that annually 300 000 cases of rotavirus-induced gastroenteritis (RVGE) occur in children aged up to 5 years in France. A two-dose vaccine against rotavirus infection (RIX4414; Rotarix, GlaxoSmithKline), has been shown to be highly effective against severe RVGE. OBJECTIVE:This study evaluate...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256134
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0442-2
更新日期:2019-04-01 00:00:00
abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/BF03261872
更新日期:2012-11-01 00:00:00
abstract::There is wide consensus that the ways in which providers are reimbursed by third parties will affect their behaviour and, hence, the efficient use of limited resources and the performance of health systems. However, there seems to be little evidence on how payment to hospital-based doctors affects hospital performance...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:
更新日期:2003-01-01 00:00:00
abstract::The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic assessments based on c...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11590150-000000000-00000
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND:Early awareness and alert systems have been established in many countries but evidence on their ability to accurately prioritize new medicines (for early assessment) is limited. OBJECTIVE:The purpose of this study was to assess whether the Swedish Early Awareness and Alert System identified and prioritized ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0434-2
更新日期:2019-02-01 00:00:00
abstract:OBJECTIVES:Invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children < 5 years of age in New Zealand (NZ), with marked disparities across socio-economic and ethnic groups. This cost-effectiveness evaluation aims to compare the potential impact o...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0387-5
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US. OBJECTIVES:The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US. METHODS:From a privately ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11592430-000000000-00000
更新日期:2011-09-01 00:00:00
abstract::This paper examines the use of propensity score matching in economic analyses of observational data. Several excellent papers have previously reviewed practical aspects of propensity score estimation and other aspects of the propensity score literature. The purpose of this paper is to compare the conceptual foundation...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0075-4
更新日期:2014-02-01 00:00:00
abstract::This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-021-00636-6
更新日期:2021-01-25 00:00:00
abstract:BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11531500-000000000-00000
更新日期:2011-03-01 00:00:00
abstract:OBJECTIVE:Compared to traditional drugs, specialty drugs tend to be indicated for lower prevalence diseases. Our objective was to compare the potential population health benefits associated with specialty and traditional drugs in the year following product approval. METHODS:First, we created a dataset of estimates of ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0291-9
更新日期:2017-04-01 00:00:00
abstract:AIM:To assess the relative cost effectiveness of four strategies (academic detailing, computerised reminder systems, target payments and interactive continuing medical education) to increase the provision of screening and brief interventions by Australian GPs with the ultimate goal of decreasing risky alcohol consumpti...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200605030-00002
更新日期:2006-01-01 00:00:00
abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00496-1
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Cost-effectiveness analyses (CEAs) have been performed for oral non-disease-altering osteoarthritis (OA) treatments for well over a decade. During that period the methods for performing these analyses have evolved as pharmacoeconomic methods have advanced, new treatments have been introduced, and the knowled...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-013-0061-x
更新日期:2013-12-01 00:00:00
abstract:BACKGROUND:In Slovenia during the period 2000-2010, the number of years of potential life lost before the age of 70 years per 100,000 population under 70 years of age declined 25 %. OBJECTIVE:The aim of this study was to test the hypothesis that pharmaceutical innovation played a key role in reducing premature mortali...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-014-0144-3
更新日期:2015-04-01 00:00:00
abstract:BACKGROUND:Limited empirical evidence exists regarding the effect of price changes on hospital behavior and, ultimately, the quality of care. Additionally, an overview of the results of prior literature is lacking. OBJECTIVE:This study aims to provide a synthesis of existing research concerning the relationship betwee...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-020-00577-6
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate. OBJECTIVE:To determine cancer-related medical care costs for long-term survivors of HCC. METHODS:The estimation of the lifetim...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200806010-00005
更新日期:2008-01-01 00:00:00
abstract:OBJECTIVES:To analyse the cost effectiveness of community-based case management for patients suffering from chronic obstructive pulmonary disease (COPD). METHODS:The study took place in the third largest municipality in Denmark and was conducted as a randomised controlled trial with 12 months of follow-up. A total of ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0298-2
更新日期:2017-06-01 00:00:00
abstract::The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256149
更新日期:2009-01-01 00:00:00
abstract::In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental cost-effectiveness ratio (ICER) of a n...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11586640-000000000-00000
更新日期:2011-03-01 00:00:00
abstract:BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the exte...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-012-0002-0
更新日期:2013-02-01 00:00:00
abstract:BACKGROUND:Concerns about the long-term sustainability of health care expenditures (HCEs), particularly prescribing expenditures, has become an important policy issue in most developed countries. Previous studies suggest that proximity to death (PTD) has a significant effect on total HCEs, with its exclusion leading to...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-014-0121-x
更新日期:2014-12-01 00:00:00
abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/BF03256162
更新日期:2010-01-01 00:00:00